Get notified when AMIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Accumulated deficit rose from $50.4M to $67.1M, operating cash outflow widened from $8.3M to $12.3M, and working capital fell from $7.9M to $5.9M, indicating a materially weaker liquidity position.
- Delisting (new) — The company received a Nasdaq deficiency letter for a sub-$1.00 bid price and faces potential delisting if compliance is not regained by July 13, 2026.
- Material Weakness (worsened) — The company continues to disclose material weaknesses in internal control over financial reporting, with no remediation as of March 31, 2026.
Autonomix pauses expansion study, narrows focus to pancreatic cancer pain; operating loss widens 47% to $17.0M
Filed May 27, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~1 min read
Key Changes
-
high
Company paused enrollment in its expansion study after variable early outcomes and refocused on severe pancreatic cancer pain, with U.S. trials expected late 2026 pending financing.
Business verify on EDGAR → -
high
Operating loss widened 47% to $17.0M, driven by higher R&D and G&A spending; net loss was $16.7M.
MD&A verify on EDGAR → -
high
Cash runway extended to Q4 2026, but going-concern doubt persists as accumulated deficit rose to $67.1M and working capital fell to $5.9M.
MD&A verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade AMIX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 4, 2026 · How we verify